Orgenesis (NASDAQ:ORGS) and Oragenics (NYSE:OGEN) Critical Contrast

Risk & Volatility

Oragenics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.19, suggesting that its share price is 219% more volatile than the S&P 500.

Earnings and Valuation

This table compares Oragenics and Orgenesis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oragenics	N/A	N/A	-$20.66 million	($21.42)	-0.06
Orgenesis	$662,000.00	7.25	-$55.36 million	N/A	N/A

Oragenics has higher earnings, but lower revenue than Orgenesis.

Profitability

This table compares Oragenics and Orgenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oragenics	N/A	-2,087.95%	-486.56%
Orgenesis	-3,827.81%	N/A	-130.18%

Institutional & Insider Ownership

18.7% of Oragenics shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 4.9% of Oragenics shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Orgenesis beats Oragenics on 6 of the 8 factors compared between the two stocks.

About Oragenics

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

About Orgenesis

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.